Compare
Clene Inc. vs Lisata Therapeutics, Inc. vs Serina Therapeutics, Inc. vs Allarity Therapeutics, Inc.
| Latest fiscal year | Clene Inc. CLNN | Lisata Therapeutics, Inc. LSTA | Serina Therapeutics, Inc. SER | Allarity Therapeutics, Inc. ALLR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $200.0K | $170.0K | $130.0K | $320.0K |
| Revenue growth (YoY) | -41.5% | -83.0% | +132.1% | n/a |
| Gross margin | 78.5% (computed) | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$26.17M | -$16.59M | -$19.18M | -$11.23M |
| EPS (Diluted) | n/a | -$1.91 | -$1.91 | n/a |
| Operating cash flow | -$18.55M | -$15.95M | -$17.95M | -$14.82M |
| Free cash flow | -$18.59M | -$15.98M | -$18.01M | -$14.83M |
| Cash & equivalents | $5.19M | $15.96M | $3.06M | $14.69M |
| Total assets | $18.13M | $17.74M | $6.95M | $18.26M |
| Total liabilities | $35.72M | $3.14M | $6.99M | $8.43M |
| Shareholders' equity | -$17.59M | $14.86M | -$37.0K | $9.83M |
| Return on year-end equity | n/a | -111.7% | n/a | -114.3% |
| Shares outstanding | 10.85M | 8.83M | 10.77M | 16.08M |
Revenue, most recent five fiscal years
| Fiscal year | Clene Inc. | Lisata Therapeutics, Inc. | Serina Therapeutics, Inc. | Allarity Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $200.0K Ended 2025-12-31 | $170.0K Ended 2025-12-31 | $130.0K Ended 2025-12-31 | $320.0K Ended 2025-12-31 |
| 1 year earlier | $342.0K Ended 2024-12-31 | $1.00M Ended 2024-12-31 | $56.0K Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $654.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $3.15M Ended 2023-12-31 | n/a |
| 3 years earlier | $473.0K Ended 2022-12-31 | $0 Ended 2022-12-31 | $34.0K Ended 2022-12-31 | n/a |
| 4 years earlier | $723.0K Ended 2021-12-31 | n/a | $144.0K Ended 2021-12-31 | n/a |